Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee (ALBATROSS-3)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02205814 |
|
Recruitment Status :
Completed
First Posted : July 31, 2014
Results First Posted : September 16, 2015
Last Update Posted : November 3, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
This study is designed as a double-blind, randomised, placebo-controlled, four parallel arm, dose-finding study, to be conducted in approximately 26 sites, to evaluate the efficacy, safety, tolerability, and pharmacokinetics of single intra-articular (IA) injections of fasitibant in patients with symptomatic osteoarthritis (OA) of the knee.
Approximately 400 male and female patients 40-80 years old, with BMI < 30 kg/m² and with a clinical diagnosis of symptomatic primary osteoarthritis of the knee will be randomised to a total of 4 treatment arms. Each arm includes a single intra-articular injection of one of three dosages of fasitibant (low, intermediate and high dose) OR placebo. The randomisation ratio will be 1:1:1:1.
The primary efficacy variable will be the change of the Western Ontario and McMaster Universities Visual Analogue Scale 3.1 A (WOMAC VA 3.1 A) (total pain) subscore from baseline up to 2 weeks after randomisation. Safety will be assessed by monitoring adverse events and clinical laboratory tests; local tolerability at the injection site will also be assessed. In addition, the population pharmacokinetics and the exposure-response relationship will be evaluated.
The individual experimental clinical phase will last up to maximal 15 weeks encompassing 7 planned visits at site, including screening, randomisation, 4 follow-up visits and the End of study visit.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Knee Osteoarthritis | Drug: Fasitibant- low dose Drug: Fasitibant- intermediate dose Drug: Fasitibant- high dose Drug: Placebo comparator | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 436 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Double-blind, Randomised, Placebo-controlled, Four Parallel Arm, Dose-finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Single Intra-articular Injections of Fasitibant in Patients With Symptomatic Osteoarthritis of the Knee. |
| Study Start Date : | April 2014 |
| Actual Primary Completion Date : | January 2015 |
| Actual Study Completion Date : | January 2015 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Fasitibant low dose
Drug: solution for intra-articular injection
|
Drug: Fasitibant- low dose
Single intra-articular injection of low dose of fasitibant |
|
Experimental: Fasitibant intermediate dose
Drug: solution for intra-articular injection
|
Drug: Fasitibant- intermediate dose
Single intra-articular injection of intermediate dose of fasitibant |
|
Experimental: Fasitibant high dose
Drug: solution for intra-articular injection
|
Drug: Fasitibant- high dose
Single intra-articular injection of high dose of fasitibant |
|
Placebo Comparator: PLACEBO
Drug: solution for intra-articular injection
|
Drug: Placebo comparator
Single intra-articular injection of placebo |
- Change in WOMAC A [ Time Frame: from baseline up to 2 weeks after randomisation ]The validated Western Ontario and McMaster University questionnaire (WOMAC) was used to measure total knee pain choosing its visual analogue scale version (VAS). The WOMAC VA 3.1 A subscore (WOMAC A) ranges from 0 to 500 mm (summing up five VAS 0-100 mm) with higher scores indicating more pain.
- Change in WOMAC INDEX [ Time Frame: from baseline up to 6 weeks after randomisation ]The WOMAC VA 3.1 Index score (WOMAC INDEX) is the sum of WOMAC A (total pain), WOMAC B (stiffness) and WOMAC C (functional impairment) subscores. The WOMAC INDEX score ranges from 0 to 2400 mm, with higher scores indicating higher disease burden.
- Responder Rate According to OMERACT-OARSI Criteria [ Time Frame: from baseline up to 6 weeks after randomisation ]Percentage of responders according to Outcome Measures in Rheumatology-Osteoarthritis Research Society International criteria (OMERACT-OARSI criteria). Patients with at least 50 % improvement in pain or in function scores are considered responders. Alternatively, patients are considered responders if they show at least 20% improvement in at least two of the following scores: pain, function and Patients's Global Assessment (PGA) scores.
- Euro Quality of Life Questionnaire (EQ-5D-5L) Responder Rate [ Time Frame: from baseline up to 6 weeks after randomisation ]Response based on change ≥ 20 % from baseline for EQ-5D-5L index value
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 40 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female patients aged 40 to 80 years with BMI < 30 kg/m²
- Patient with Kellgren-Lawrence Grade 2 to 3, symptomatic primary osteoarthritis at the index knee (ACR criteria), for which an IA treatment is indicated
- Pain of moderate to severe intensity, even if treated with chronic doses of non steroidal antinflammatory drugs
Exclusion Criteria:
- History of hypersensitivity/allergy to drugs including paracetamol and to disinfectants
- Any pharmacological treatment of concomitant disease(s) started or changed during 4 weeks prior to randomisation, or likely to be changed during the course of the study
- Use of systemic or topical corticosteroids > 10 mg prednisolone equivalent per day, or immunosuppressant drugs
- Current use of any pain or OA medication (e.g. NSAIDs, COX-2 inhibitors, analgesics, antidepressive agents), including topical treatments
- Viscosupplementation to the target knee administered < 4 months prior to randomisation and/or scheduled during the course of the study
- Evidence of clinically significant hepatic disease or of moderate or severe renal insufficiency
- Current use of any medications that are substrate of CYP3A4 and/or moderate or strong CYP3A4 inhibitors
- Patients with any clinically relevant or unstable disease, or malignant neoplasms that, in the opinion of the Investigator, may pose the patient at risk, or confound the efficacy and safety results of the study
- Patients with any clinically relevant abnormal safety laboratory test results, and/or abnormalities in vital signs, and/or ECG parameters
- Pregnant and breastfeeding women
- Any sign of significant immunodeficiency, systemic infection, knee infection or knee bursitis
- Patients with bleeding diathesis or on therapy with anticoagulants
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02205814
Show 25 study locations
| Study Chair: | Karel Pavelka, Professor | Institute of Rheumatology, Charles University Faculty Hospital, Na Slupi 4, 128 50 Prague 2, Czech Republic |
| Responsible Party: | Menarini Group |
| ClinicalTrials.gov Identifier: | NCT02205814 |
| Other Study ID Numbers: |
BKOS-04 2013-004999-35 ( EudraCT Number ) |
| First Posted: | July 31, 2014 Key Record Dates |
| Results First Posted: | September 16, 2015 |
| Last Update Posted: | November 3, 2015 |
| Last Verified: | October 2015 |
|
Osteoarthritis, Knee Arthritis WOMAC |
Injections, intra-articular Fasitibant MEN 16132 |
|
Osteoarthritis Osteoarthritis, Knee Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases (4-amino-5-(4-(4-(2,4-dichloro-3-(2,4-dimethyl-8-quinolyloxymethyl)phenylsulfonamido)tetrahydro-2H-4-pyranoylcarbonyl)piperazino)-5-oxopentyl)(trimethyl)ammonium |
Bradykinin B2 Receptor Antagonists Bradykinin Receptor Antagonists Molecular Mechanisms of Pharmacological Action Complement Inactivating Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |